Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00166894
Status:
UNKNOWN
Last Update Posted:
2005-11-24
First Post:
2005-09-12
Brief Title:
Use of the Triggering Receptor Expressed on Myeloid Cells-1 TREM-1 in the Diagnosis of Pleural Effusion
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Evaluation of the Triggering Receptor Expressed on Myeloid Cells-1 TREM-1 as a Diagnostic Tool for Patients With Pleural Effusion
Status:
UNKNOWN
Status Verified Date:
2005-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this trial is to evaluate the level of TREM-1 in different kinds of pleural effusion
Detailed Description:
The triggering receptor expressed on myeloid cells-1 TREM-1 is a member of the immunoglobulin superfamily and its expression is upregulated on phagocytic cells in the presence of bacteria or fungi Several experiments by Bouchon and colleagues showed that TREM-1 mediates the acute inflammatory response to microbial products Human tissues infected with bacteria are infiltrated with neutrophils and macrophages that express high levels of TREM-1 Conversely TREM-1 is only weakly expressed in samples from patients with noninfectious inflammatory disorders In addition TREM-1 is shed from the membrane of activated phagocytes and can be found in a soluble form in body fluids The presence of a soluble form of TREM-1 in samples of bronchoalveolar lavage fluid from mechanically ventilated patients has been shown to be a good indicator of infectious pneumonia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None